135 related articles for article (PubMed ID: 29214578)
21. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.
Lord J; Thomason MJ; Littlejohns P; Chalmers RA; Bain MD; Addison GM; Wilcox AH; Seymour CA
J Epidemiol Community Health; 1999 Mar; 53(3):179-86. PubMed ID: 10396496
[TBL] [Abstract][Full Text] [Related]
22. Cost-of-Illness in Rare Diseases.
Linertová R; García-Pérez L; Gorostiza I
Adv Exp Med Biol; 2017; 1031():283-297. PubMed ID: 29214579
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of newborn screening for sickle cell disease: a systematic review protocol.
Mahapatra B; Mukherjee N; Khatoon S; Bhattacharya P; Thubru E; John D
JBI Evid Synth; 2024 Jun; 22(6):1143-1150. PubMed ID: 38287736
[TBL] [Abstract][Full Text] [Related]
24. Potential costs and benefits of newborn screening for severe combined immunodeficiency.
McGhee SA; Stiehm ER; McCabe ER
J Pediatr; 2005 Nov; 147(5):603-8. PubMed ID: 16291349
[TBL] [Abstract][Full Text] [Related]
25. The economics of screening infants at risk of hearing impairment: an international analysis.
Burke MJ; Shenton RC; Taylor MJ
Int J Pediatr Otorhinolaryngol; 2012 Feb; 76(2):212-8. PubMed ID: 22129917
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.
Tran K; Banerjee S; Li H; Noorani HZ; Mensinkai S; Dooley K
Clin Biochem; 2007 Feb; 40(3-4):235-41. PubMed ID: 17222812
[TBL] [Abstract][Full Text] [Related]
27. Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.
Langer A; Holle R; John J
BMC Health Serv Res; 2012 Sep; 12():300. PubMed ID: 22947299
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of establishing a neonatal screening programme for phenylketonuria in Libya.
Sladkevicius E; Pollitt RJ; Mgadmi A; Guest JF
Appl Health Econ Health Policy; 2010; 8(6):407-20. PubMed ID: 21043542
[TBL] [Abstract][Full Text] [Related]
29. Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness.
Ewer AK; Furmston AT; Middleton LJ; Deeks JJ; Daniels JP; Pattison HM; Powell R; Roberts TE; Barton P; Auguste P; Bhoyar A; Thangaratinam S; Tonks AM; Satodia P; Deshpande S; Kumararatne B; Sivakumar S; Mupanemunda R; Khan KS
Health Technol Assess; 2012; 16(2):v-xiii, 1-184. PubMed ID: 22284744
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of tandem mass spectrometry screening in California.
Feuchtbaum L; Cunningham G
Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
[TBL] [Abstract][Full Text] [Related]
31. QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique.
Grosse SD; Prosser LA; Asakawa K; Feeny D
Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):293-308. PubMed ID: 20545594
[TBL] [Abstract][Full Text] [Related]
32. Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations.
Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
J Cyst Fibros; 2018 May; 17(3):306-315. PubMed ID: 29572018
[TBL] [Abstract][Full Text] [Related]
33. Expanded newborn screening: social and ethical issues.
Dhondt JL
J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S211-7. PubMed ID: 20544288
[TBL] [Abstract][Full Text] [Related]
34. [Programs of systematic screening in neonatology. Pharmaco-economic aspects].
Schoos R; Verloes A; Bourguignon JP; Koulischer L
Rev Med Liege; 1998 May; 53(5):311-5. PubMed ID: 9689890
[TBL] [Abstract][Full Text] [Related]
35. Cost analysis: concepts and application.
Brosnan CA; Swint JM
Public Health Nurs; 2001; 18(1):13-8. PubMed ID: 11251868
[TBL] [Abstract][Full Text] [Related]
36. [A short-term diagnostic and economic impact model of neonatal screening for cystic fibrosis].
Rasch A; Perleth M
Klin Padiatr; 2011 Mar; 223(2):96-103. PubMed ID: 21305445
[TBL] [Abstract][Full Text] [Related]
37. A primer on economic evaluations related to expansion of newborn screening for genetic and metabolic disorders.
Hubbard HB
J Obstet Gynecol Neonatal Nurs; 2006; 35(6):692-9. PubMed ID: 17105633
[TBL] [Abstract][Full Text] [Related]
38. [Controversial Issues in Economic Evaluation (III): health Care Interventions in Special Situations].
Espín Balbino J; Brosa Riestra M; Oliva Moreno J; Trapero-Bertran M;
Rev Esp Salud Publica; 2015; 89(3):237-47. PubMed ID: 26388338
[TBL] [Abstract][Full Text] [Related]
39. Cost and cost-effectiveness of universal screening for hearing loss in newborns.
Kezirian EJ; White KR; Yueh B; Sullivan SD
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):359-67. PubMed ID: 11283492
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands.
van der Hilst CS; Derks TG; Reijngoud DJ; Smit GP; TenVergert EM
J Pediatr; 2007 Aug; 151(2):115-20, 120.e1-3. PubMed ID: 17643759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
